Skip to main content

Research Repository

Advanced Search

The discovery of a novel antimetastatic Bcl3 inhibitor

Soukupová, Jitka; Bordoni, Cinzia; Turnham, Daniel J.; Yang, William W.; Seaton, Gillian; Gruca, Aleksandra; French, Rhiannon; Lee, Kok Yung; Varnava, Athina; Piggott, Luke; Clarkson, Richard W.E.; Westwell, Andrew D.; Brancale, Andrea

The discovery of a novel antimetastatic Bcl3 inhibitor Thumbnail


Authors

Jitka Soukupová

Cinzia Bordoni

Daniel J. Turnham

William W. Yang

Gillian Seaton

Aleksandra Gruca

Rhiannon French

Kok Yung Lee

Athina Varnava

Luke Piggott

Richard W.E. Clarkson

Andrew D. Westwell

Andrea Brancale



Abstract

The development of antimetastatic drugs is an urgent healthcare priority for patients with cancer, because metastasis is thought to account for around 90% of cancer deaths. Current antimetastatic treatment options are limited and often associated with poor long-term survival and systemic toxicities. Bcl3, a facilitator protein of the NF-κB family, is associated with poor prognosis in a range of tumor types. Bcl3 has been directly implicated in the metastasis of tumor cells, yet is well tolerated when constitutively deleted in murine models, making it a promising therapeutic target. Here, we describe the identification and characterization of the first small-molecule Bcl3 inhibitor, by using a virtual drug design and screening approach against a computational model of the Bcl3-NF-kB1(p50) protein–protein interaction. From selected virtual screening hits, one compound (JS6) showed potent intracellular Bcl3-inhibitory activity. JS6 treatment led to reductions in Bcl3-NF-kB1 binding, tumor colony formation, and cancer cell migration in vitro; and tumor stasis and antimetastatic activity in vivo, while being devoid of overt systemic toxicity. These results represent a successful application of in silico screening in the identification of protein–protein inhibitors for novel intracellular targets, and confirm Bcl3 as a potential antimetastatic target.

Journal Article Type Article
Acceptance Date Feb 24, 2021
Online Publication Date Mar 1, 2021
Publication Date May 1, 2021
Deposit Date Oct 22, 2024
Publicly Available Date Oct 29, 2024
Journal Molecular Cancer Therapeutics
Print ISSN 1535-7163
Electronic ISSN 1538-8514
Publisher American Association for Cancer Research
Peer Reviewed Peer Reviewed
Volume 20
Issue 5
Pages 775-786
DOI https://doi.org/10.1158/1535-7163.mct-20-0283
Public URL https://uwe-repository.worktribe.com/output/13307554

Files





You might also like



Downloadable Citations